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Abstract 
ADAM23 belongs to the ADAM (A Disintegrin And 
Metalloproteinase domain) family of proteins. 
Members of this family present a common structural 
organization including metalloprotease, disintegrin, 
cystein-rich, epidermal growth factor-like, 
transmembrane and cytoplasmatic domains and are 
structurally related to snake venom disintegrins. 
ADAM23 has close similarity to ADAM11 and 
ADAM22; is highly expressed in the CNS, and is 
crucial for normal brain development. Mice 
homozygous for an insertional mutation that 
inactivates the gene are smaller than normal 
littermates, show delayed lung development, are 
lethal by postnatal day 14, and display severe tremor 
and ataxia.  
ADAM23 does not present metalloprotease activity  
and probably plays its biological role through the 
disintegrin domain. ADAM23 is involved in cell-cell 
adhesion and communication and cell-matrix 
modulation.  
The ADAM23 gene is frequently silenced by DNA 
promoter methylation in different types of solid 
cancers and epigenetic inactivation is associated 
with cancer progression, increased tumor cell 
mobility and reduced tumor cell proliferation. 
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Identity 
Other names: MDC3 
HGNC (Hugo): ADAM23 
Location: 2q33.3 
Genomic structure of ADAM23 human gene composed of 27 coding exons. Black boxes represent constitutive exons present in 
all splicing isoforms. Colored boxes represent alternatively spliced exons. 
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Domain structure of ADAM23. Its deduced amino acid sequence lacks essential residues conserved in metalloproteinases 
(adapted from Cal et al., 2000). 
 
 
DNA/RNA 
Description 
DNA contains 177488 bp composed of 27 coding 
exons (26 reported by RefSeq sequences). 
Transcription 
6236 bp mRNA transcribed (RefSeq NM_003812.3) 
in centromeric to telomeric orientation; 2499 bp 
open reading frame. There are three alternative 
splicing isoforms of the human ADAM23 gene: 
ADAM23-alpha (chosen as the 'canonical' 
sequence), ADAM23-beta and ADAM23-gamma. 
These splicing isoforms are generated by the 
mutually exclusive use or skipping of the exons 25 
and/or 26, both of which coding for transmembrane 
domains with different aminoacid compositions. The 
ADAM23 proteins encoded by the alpha and beta 
splicing isoforms are anchored to the membrane by 
different transmembrane domains (encoded by exon 
26 in the isoform alpha and by exon 25 in the isoform 
beta) and are predicted to have distinct membrane 
subdomain localizations. ADAM23-gamma is 
generated by exon skipping of exons 25 and 26 and 
therefore lacks the transmembrane domain and is 
predicted to be either a cytoplasmatic or a secreted 
isoform of the ADAM23 protein. ADAM23 mRNA 
is detected at high or medium expression levels in 
brain, testis and heart muscle (The Human Protein 
Atlas, ENSG00000114948). 
Pseudogene 
No pseudogenes reported. 
Protein 
Description 
ADAM23 is a non-catalytically active member of 
ADAM family and exhibits all the conserved protein 
domains, including: an N-terminal signal, a pro-
domain, a metalloprotease and a disintegrin 
domains, a cysteine-rich region, an EGF-like 
domain, a transmembrane and a short cytoplasmic 
domains. Within the metalloprotease domain, 
ADAM23 lacks the conserved zinc-binding 
sequence HEXXHXXGXXH, which is critical for 
the proteinase activity. Interacts with LGI1, LGI3 
and LGI4 (leucine-rich glioma inactivated family), 
alphav-beta3 integrins and PrPc proteins. 
Size: 832 amino acid; 92 kDa predicted (RefSeq 
NP_003803). 
Expression 
Detected at medium/high expression levels in 46 of 
82 analyzed normal tissue types, including: brain, 
testis, lung, breast, colon, pancreas and kidney 
(according to The Human Protein Atlas). 
Localisation 
Cell membrane; single-pass type I membrane protein 
(isoform ADAM23-alpha and ADAM23-beta). 
Secreted protein (predicted for ADAM23-gama 
isoform). 
Function 
ADAM23 was originally described to promote 
neuroblastoma and astrocytoma cell-cell adhesion 
via direct interaction with alphavbeta3 integrin. 
Following reports showed that the interaction 
between ADAM23 and alphavbeta3 integrin inhibits 
cell-matrix adhesion and negatively modulates 
alphavbeta3 activation during metastatic 
progression. Silencing of the ADAM23 gene 
promotes cell cycle arrest and terminal 
differentiation in P19 mice embryonic carcinoma 
cells and, in MDA-MB435 and SK-Mel37 tumor cell 
lines, promotes tumor cell migration and invasion 
and inhibits tumor cell proliferation. 
Homology 
H. sapiens: ADAM23, P. troglodytes: ADAM23, C. 
lupus: LOC607871, M. musculus: ADAM23, R. 
novergicus: ADAM23, G. gallus: LOC424099. 
Mutations 
Note 
No mutations have been reported for ADAM23 
gene. 
Germinal 
No germline mutations have been reported for the 
ADAM23 gene (OMIM603710). 
Somatic 
No somatic point mutations and CNVs have been 
reported. 
Epigenetics 
Epigenetic silencing of the ADAM23 have been 
frequently reported in different types of solid tumors. 
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Immunohistochemistry staining of ADAM23 protein in normal colon and normal breast tissues was carried out using the 
polyclonal antibody anti-ADAM23 (HPA012130, Sigma) (photograph courtesy of Dra. Gabriela F Barnabe from Ludwig Institute 
for Cancer Research - SP - Brazil). 
 
Implicated in 
Breast carcinoma 
ADAM23 expression is downregulated by promoter 
hypermethylation during breast cancer progression 
and hypermethylation was significantly associated 
with a higher incidence of distant metastasis and 
reduced overall survival. Recently, ADAM23 
epigenetic silencing during tumor progression was 
shown to generate genetic and functional 
heterogeneity in invasive breast tumors. ADAM23-
intratumoral heterogeneity (ADAM23-ITH) was 
observed in topographically distinct areas of 
undifferentiated breast invasive ductal carcinomas, 
with invasive components being frequently 
composed by mosaic clusters of ADAM23-positive 
tumor cells coexisting in close proximity with 
ADAM23-silenced cells. Most importantly, it was 
demonstrated that ADAM23-ITH promotes tumor 
growth and metastasis by establishing a crosstalk 
between ADAM23-positives and ADAM23-
negatives tumor cells in which ADAM23-negative 
cells promote tumor growth and metastasis by 
enhancing the proliferation and invasion of adjacent 
ADAM23-positive cells through the production of 
the ADAM23-ligant LGI4 (leucine-rich glioma 
Inactivated gene 4) and pro-migratory levels of nitric 
oxide (NO). 
Lung carcinoma 
ADAM23 protein levels is lower in non-small-cell 
lung carcinoma (NSCLC) compared to 
corresponding normal tissues and benign pulmonary 
lesions, and a decrease in ADAM23 protein 
expression was observed during NSCLC 
progression. Hypermethylation of ADAM23 
promoter region was observed in 40% of NSCLC but 
in only 7.6% of the adjacent normal tissues. 
Gastric tumors 
ADAM23 promoter hypermethylation is frequently 
observed in gastric dysplasia (90%) and gastric 
tumors (29-55%) but is rarely observed in normal 
mucosa (9%). The frequency of ADAM23 
methylation is higher in metastatic lesions compared 
to paired primary tumors. Homozygous loss of 
ADAM23 was also reported for gastric tumors but at 
a lower frequency (~3%). 
Pancreatic tumors 
ADAM23 promoter methylation was detected in 7 
out of 24 (29%) primary invasive pancreatic ductal 
adenocarcinomas. 
Head and neck cancer 
ADAM23 promoter hypermethylation was detected 
in 18 out of 43 head and neck tumors (42%) and a 
significant association between ADAM23 
hypermethylation and advanced stages (T3-T4) was 
observed larynx tumors. 
Multiple myeloma 
ADAM23 mRNA expression is absent in normal 
bone marrow plasma cells, but is aberrantly 
expressed in 2/131 (1,5%) patients with newly 
diagnosed multiple myeloma. In two independent 
cohorts of patients with primary multiple myeloma, 
24 out of 557 patients (4%) showed increased levels 
of ADAM23 mRNA expression, which was 
significantly associated with poor overall survival. 
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